Elanco

Intestinal tapeworms are a real threat for both dogs and humans. These worms can easily be transmitted from your pet to you, taking exposure from "ick" to "sick". Dr. Elise Kelly, Elanco Senior Regional Consulting Veterinarian, joined Fox28 Columbus to discuss the risks and symptoms of tapeworms, how dogs can contract them and the importance of year-round protection. #WeAreElanco https://bit.ly/4gdxgzc

25,000. That’s how many hours our global team has committed to volunteering by 2025. Last year, our team recorded more than 23,600 volunteer hours supporting causes to improve animal welfare, community services, food security and education worldwide. But that’s just the start. Officially one month out from our annual Global Day of Purpose- an event to kick off a month of giving and volunteerism- our team is gearing up to make this year our biggest yet! #WeAreElanco #GDOP2024

Canine parvovirus is one of the most contagious and deadly viruses for dogs and puppies. Until recently, the only treatment was supportive care. That changed with our USDA-conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA). Now, veterinarians, pet owners and puppies have a chance to fight back against this deadly disease. 📸 1: CPMA-treated parvo survivor Mia, 4 months from Woodstock, IL, Helping Paws Animal Shelter 📸 2: CPMA-treated parvo survivor Spaz, 3 months old from Papillion, NE, Papillion Animal Hospital 📸 3: CPMA-treated parvo survivor Yeti, 3 months old from San Leon, TX, Bay Area Pet Adoptions #WeAreElanco

Up to 900 dogs are diagnosed with canine parvovirus each day.(1) When left untreated, this disease has a mortality rate of up to 91%.(2) But with the USDA-conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA), we’re changing the game. Based on real world usage, 93% of patients treated with CPMA survived.(3) 📸 1: CPMA-treated parvo survivor Walter Danahue, 3 months old from San Diego, CA, Tell Tail Veterinary Urgent Care 📸 2: CPMA-treated parvo survivor Charlie, 3 months old from Wesley Chapel, FL, Seven Oaks Pet Hospital 📸 3: CPMA-treated parvo survivor Mabel, 3 months old from Mattoon, IL, Albin Animal Hospital #WeAreElanco 1: Elanco Animal Health. Data on file. 2: Venn EC, JVET Emerg Crit Care. 2017. 3: Elanco. Market Data on file.

Saving puppies and creating jobs – we can’t think of a better reason to celebrate. Our Elwood, Kansas manufacturing site produces and ships our Canine Parvovirus Monoclonal Antibody – the first and only USDA conditionally approved, targeted treatment for canine parvovirus. And #ICYMI we’re just getting started. We unveiled plans for the expansion of our specialized manufacturing facility in Elwood, bringing together “the three P’s” of what truly sets us apart. 👷People: This 25,000 sq. ft. expansion project will double our production capacity and create approximately 70 new jobs by 2026. 🐶 Purpose: We’re serious about getting puppies back to playtime. We are one of only two animal health companies with monoclonal antibody treatments on the market, and the only one with a treatment for parvovirus, which has a high mortality rate, primarily affecting puppies. 📈 Potential: Drawing insights from advancements in human health, the animal health sector is focusing on antibody-based therapies. As this new market expands, our Elwood facility is poised to meet those demands to provide veterinarians and pet parents new solutions for persistent problems. Thank you to Kansas Lt. Governor David Toland and Senator Jerry Moran, the State of Kansas, the many staff of the Kansas Department of Commerce, local civic leaders in Elwood, the City of Elwood and Doniphan County, Kimberly Young and the entire Kansas City Animal Health Corridor team, and Evergy for their partnership. We look forward to our partnership with the Burns & McDonnell team leading the expansion as the primary provider of integrated design and construction services. Here’s to this next era of innovation! #WeAreElanco

Canine parvovirus kills. But with the USDA-conditionally approved Canine Parvovirus Monoclonal Antibody (CPMA), we’re fighting back. Across the U.S. more than 27,000 puppies have been saved by CPMA(1), giving puppies a second chance at life. 📸 1: CPMA-treated parvo survivor Sitka, 2 months old from New Tazewell, TN, Claiborne Animal Shelter 📸 2: CPMA-treated parvo survivor Cooper, 3 months old from Ila, GA, Ila Vet Clinic. 📸 3: CPMA-treated parvo survivor Indy, 2 months old from Myrtle Beach, SC, Hometown Veterinary Partners 📸 4: CPMA-treated parvo survivor Oats, 3 months old from Papillion, NE, Papillion Animal Hospital. #WeAreElanco #InternationalDogDay 1: Elanco Animal Health. Data on file.

Meet Noah Brown, the first technical apprentice paving the way for the new "Earn to Learn" manufacturing program at our Clinton, Indiana facility. For more than 50 years, this site has had a long history of innovation and delivering products while remaining interconnected to the community. At times, there have even been three generations of a family going to work together. This latest partnership with Ivy Tech Community College aims to build upon the community legacy by using top talent in the area. Participants in the “Earn to Learn” program will earn full-time wages while they work towards a Technical Certificate in the mechanical field. This program opens doors for people to gain valuable skills and real-world experience, all while helping advance our purpose of making life better. #WeAreElanco

Our team’s commitment to animal health extends beyond their daily job through the entire industry. Dr. Claudia O., Farm Animal Associate Advisor, was recently elected as President of the American Association of Avian Pathologists (AAAP). The AAAP is an international association with the mission to promote scientific knowledge to enhance the health, well–being and productivity of poultry to provide safe and abundant food for the world. With more than 17 years in the field, this achievement demonstrates Dr. Osorio’s commitment to poultry disease prevention and enhancing poultry health. #WeAreElanco

Today, we announced a 25,000-square-foot expansion of our biologics manufacturing facility in Elwood, Kansas. This new investment will enable further growth in our monoclonal antibody (mAb) platform, building on the robust expertise already present at the facility. The animal health sector is increasingly focusing on antibody-based therapies, drawing insights from advancements in human health. These therapies are recognized for their effectiveness and the potential for faster resolution of clinical signs or severe disease. They will be fundamental in enhancing the quality of life for pets and strengthening the human-animal bond. Burns & McDonnell is serving as the design-build partner on this project. Learn more: https://bit.ly/3SVXT1F

🚨Exciting Innovation Update🚨 Our era of innovation continues. Today, we announced that Credelio Quattro, our broad-spectrum parasiticide, is moving to the Food and Drug Administration (FDA) final 60-day administrative review phase. U.S. approval is expected in October 2024 and launch expected in Q1 2025. We now expect to launch a potential blockbuster each of the next three quarters in large, fast-growing or new markets that are largely accretive to Elanco: - Q3 2024: Bovaer, the only FDA-reviewed feed ingredient with a methane-reduction claim, launching in the U.S. dairy market - Q4 2024: Zenrelia, our JAK inhibitor, launching in the fast-growing canine dermatology market - Q1 2025: Credelio Quattro, our broad-spectrum parasiticide, launching in the largest pet health market We continue to expect $600 million to $700 million of innovation sales in 2025. “We are very pleased with the continued progress of our pipeline,” said Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs. “We completed the Bovaer review ahead of schedule and now have two potential blockbusters – Zenrelia and Credelio Quattro – in the final administrative review at FDA, illustrating our R&D organization’s high capacity and ability to build capabilities to deliver a consistent flow of high impact innovation. A significant thank you to the Elanco team for their efforts to bring these differentiated innovations toward approval while also refilling and advancing the early-stage pipeline for the next era of innovation.” Read more here: https://bit.ly/3SUgye2